Schott and Credence MedSystems have formed a strategic collaboration to make syringe injections safer through integration of Schott’s pre-fillable syriQ glass and the Credence Companion technology.
As reported in an Oct. 5, 2020 press release, the companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for drug delivery via prefilled syringes. The combination of Schott’s and Credence’s offerings targets a pre-validated and pre-assembled portfolio of passive integrated needle systems with various available syringe sizes made of both glass and high-quality Cyclic Olefin Copolymer materials.
“Integrating our established Companion technology with a broad variety of existing syringe barrels from Schott is an important milestone in offering innovation without change to the pharmaceutical industry,” said John Merhige, Credence’s chief commercial officer, in the press release. “This allows pharma the confidence to work with already validated systems but the freedom to choose the perfect fit from a wide portfolio.”
Fabian Stöcker, vice president of Global Strategy and Innovation at Schott Pharmaceutical Systems added, in the press release, “Having over 20 years of experience in the field of syringes, we are happy that, with this partnership and product offering, we can even go a step further to create a new, synergistic, and trusted offering for glass and polymer syringe systems that is responsive to the growing needs of the industry. To our knowledge, we will provide the first integrated needle safety system on the market with a polymer pre-fillable syringe by integrating the Credence Companion technology into our Schott TOPPAC syringes.”
The new EU Falsified Medicines Directive requires the outer packaging of any medicine to be provided with the following features
1. “Security features which make it possible for wholesalers and persons who are empowered or authorized to dispense medicines to the public to verify the authenticity of the medicine and to identify single packs
2. As well as a device which makes it possible to check if the outer packaging has been tampered with.”
Pharmapack will be organised in accordance with Informa’s AllSecure health and safety standard. As the world’s leading events’ organiser, Informa has developed a detailed set of enhanced measures to provide the highest levels of hygiene and safety at its events, providing everyone with reassurance and confidence they are participating in a safe and controlled environment.
Part of our strategy in delivering a safe, compliant and enjoyable event is making the experience as comfortable as possible for our attendees. This is why, for 2021 we have taken the decision to host all of our content digitally, in the two weeks prior to the live event.
Pharmapack is the European hub for the pharma packaging and drug delivery device industry. Taking place annually in Paris, the event unites over 5,500 attendees and 410+ exhibitors for two days of innovation, networking and education.
Diabetes patients depending on lifelong insulin treatment have to administer the vital medication to themselves using insulin pumps, syringes or pens. Ypsomed offers UnoPen™, a disposable pen with variable dose setting, for this and other multidose therapies. Schreiner MediPharm has developed an NFC-Label for this injection aid that serves as a communication interface between the injector and the SmartPilot™—an electronic pen add-on. The resulting smart device interactively supports patients in using the pen and helps them adhere to their therapy plans.
Round nasal spray bottles with snap-on neck finish 20 mm Sterile, sterilized available. These spray bottles are available for nasal and other applications. These are snap on with 20mm neck. Available full range 10ml to 50ml.
Standard material: HDPE
• Full range from 10 ml to 50 ml
• Also suitable for crimp-on pumps
• Delivered ready-to-fill (sterile) or gamma sterilized
• Officially approved by Aptar Pharma, Nemera and Silgan
It is extremely important for the success of medical treatment that patients adhere exactly to the medication prescribed to them. Numerous studies prove that adherence to therapy pays off. But studies also show that many patients ignore their treatment plans – out of stubbornness, carelessness or excessive demands. This so-called non-adherence not only jeopardizes the success of treatment, but also causes immense costs for the health care systems.
Hoffmann Neopac, a global provider of high-quality packaging for a broad array of industries and applications, has introduced the market’s first fully recyclable polyethylene-based tubes with high-density polyethylene (HDPE) flip-top caps. A breakthrough in the worldwide push for packaging sustainability, the mono-material tube + cap combination overcomes a longstanding functionality hurdle for hinged caps, which were previously made predominantly from less recyclable polypropylene (PP) materials.
The new tube solutions are a packaging first: fully recyclable tube solutions whose body, shoulder and caps are composed of a single material family. Also available in screw-top formats, the new tubes are ideal for health & beauty, food and pharma packaging applications.
In existing recycling streams, mono-material plastic packaging is exceedingly more preferable than combination plastics, as its comparable simplicity is considered fully recyclable in mechanical recycling plants and therefore a key factor in moving toward a truly circular packaging landscape.
In addition to the new HDPE flip-top caps, Neopac also is launching a comprehensive portfolio of PE screw caps. Manufactured entirely in-house, the screw caps are available in diameters of 10-40mm.
“Achieved in collaboration with a long-time supplier, the new HDPE flip-top caps overcome the last hurdle to fully recyclable tube packaging – namely, the ability to form functional closures from the same material as the tube body and shoulder,” said Simon Böhlen, Development Engineer for Neopac. “Health & beauty, food and pharmaceuticals brands can now assure their increasingly sustainability-conscious customers that the packaging in which their products are housed has the lowest-possible environmental impact, as we move toward a fully circular packaging economy.”
The full PE Cap range is now commercially available for all Neopac’s PE, COEX, EcoDesign or Polyfoil Range. Starting November 2020, the recyclable fully mono-material PE Tubes with Flip-top cap will be available as stock solutions with the new printing service DigitAll360°.
Looking ahead, Neopac is currently in the development stages of next-generation, HDPE-optimized high-performance barrier tubes (Polyfoil® MMB) with superior decoration options. Available with PE screw-top caps, the forthcoming solutions already have received excellent ratings from Institute Cyclos-HTP, a packaging recyclability certification organization.
Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve® Nasal Naloxone TreatmentNews:
Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions and Noble, an Aptar Pharma company, world leader in drug delivery training device programs, today announced their collaboration with dne pharma, a leader in addiction medicine in Northern Europe.
Using Aptar Pharma’s patented Unidose Liquid System, Ventizolve® is a ready-to-use rescue treatment that can quickly reverse the life-threatening effects of an opioid overdose. Noble’s Unidose trainer kit, which replicates Aptar’s Unidose device, will be used by dne pharma as part of a broad patient onboarding and awareness program for Ventizolve® in outreach and drug treatment centers across the Nordics – the first trainer kit of its kind for a naloxone nasal drug product launch.
According to The World Health Organization (WHO), opioids and opioid overdose account for more than 70% of the half a million drug-use related deaths that are reported annually worldwide. In their Opioid Task Force 2020 Progress Report, the American Medical Association (AMA) states that a “continuing increase in drug overdoses is fueling the evolution of a more dangerous and complicated epidemic”, and urges stakeholders to come together to work collaboratively on meaningful action to remove barriers and increase patient access to evidence-based care, both to save lives and help end the epidemic.
Dne pharma’s focus is on improving existing treatments within addiction therapy. Nina Måsvær, Marketing Manager at dne pharma explains, “With the growing opioid overdose epidemic, we were fortunate to collaborate with Professor Ola Dale at the Norwegian University of Science and Technology in Trondheim on the development of a nasal naloxone sprayer for pre-hospital and take-home use and were able to secure final use approval for Ventizolve® in 12 European countries in 2018.”
Nasally Administered Opioid Overdose Rescue Treatment
Aptar Pharma’s Unidose Liquid System is the drug delivery device used to administer Ventizolve® and is a ready-to-use, one-step nasal device designed to enable the delivery of a precise, single dose quickly, easily and reliably, and without the need for administration by a trained professional.
“With over 100 million devices sold worldwide, our patented Unidose Technology Platforms are approved by the U.S. FDA and European regulatory authorities for a wide range of treatments from chronic conditions such as migraine and vitamin B12 deficiency to life-saving drugs that counter an opioid overdose,” commented Isabelle Menard, Director of Strategy and Business Integration at Aptar Pharma.
Noble is providing the training and onboarding component with its Unidose training device that replicates the form and function of Aptar Pharma’s Unidose drug delivery device. The Unidose training device features a novel twist reset function, making it easier for users and caregivers to practice administering a dose quickly and effectively so that they are ready when confronted with an emergency situation.
“We’re honored to provide the training support for this important initiative to combat the growing opioid overdose epidemic,” added Joe Masci, Noble’s Executive Director of Business Development. “The levels of anxiety that come with using a drug delivery device can be high under normal circumstances, let alone under stress and using a product you are not familiar with. When faced with an emergency situation, users need to have the confidence to come to someone’s aid.”
Drug Repurposing to Nasal Drug Delivery
Dne pharma is among a new generation of industry disruptors who are making their mark by repurposing existing therapies for nasal drug delivery, with benefits such as better patient convenience, greater personal empowerment, improved user compliance, and in some cases, overcoming objections to more invasive delivery routes. More importantly, in the case of a rescue treatment, the recipient does not need a healthcare professional (HCP) to administer the drug, which could be life-critical in an emergency situation where, for example, the patient is unconscious.
“Aptar Pharma’s expertise in drug repurposing using nasal delivery solutions, combined with Noble’s innovative training and onboarding platform, make them the perfect partners to support us in bringing this life-saving drug product to market,” concluded Nina Måsvær, dne pharma.
Innovative dispensing design with premium barrier protection & chemical compatibility, small-dose delivery accuracy in a sustainable way by reducing over-packaging. Perfect for dogs and cats anti-parasite, otitis and ophthalmology treatments.
What is Migration?
Migration is the transfer of chemical compounds from plastic packaging materials into food products.
These chemical compounds are usually present in inks and adhesives that travel through the primary packaging material to contaminate the contents. This can be extremely dangerous when the contents are either food or medicines.
Earlier, migration testing was only performed on containers, closures and other packaging components, excluding labels.